Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Elong Power Holding Limited (ELPW) is up 57% at $5.65 - Citizens, Inc. (CIA) is up 17% at $5.78 - The Oncology Institute, Inc. (TOI) is up 17% at $3.08 - Everbright Digital Holding Limited (EDHL) is up 12% at $3.89 - Universal Electronics Inc. (UEIC) is up 10% at $4.06 - Korro Bio, Inc. (KRRO) is up 9% at $12.57 - Silvaco Group, Inc. (SVCO) is up 9% at $3.60 - Clene Inc. (CLNN) is up 7% at $6.38 - AleAnna, Inc. (ANNA) is up 7% at $3.91 - Klarna Group plc (KLAR) is up 5% at $15.40 [3] Premarket Losers - KinderCare Learning Companies, Inc. (KLC) is down 32% at $2.30 - PAR Technology Corporation (PAR) is down 23% at $12.22 - EverCommerce Inc. (EVCM) is down 23% at $9.25 - SenesTech, Inc. (SNES) is down 21% at $1.78 - Once Upon A Farm, PBC (OFRM) is down 18% at $16.60 - PagerDuty, Inc. (PD) is down 12% at $6.35 - SciSparc Ltd. (SPRC) is down 10% at $4.25 - Agape ATP Corporation (ATPC) is down 9% at $5.09 - OIO Group (OIO) is down 9% at $3.28 - Lifetime Brands, Inc. (LCUT) is down 6% at $3.24 [4]

Core Viewpoint - SciSparc Ltd. has announced an advancement in its collaboration with NeuroThera Labs Inc. for a novel combination therapy targeting weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD) [1] Group 1: Company Overview - SciSparc Ltd. holds a controlling interest of approximately 75% in NeuroThera Labs Inc., which focuses on developing treatments for central nervous system disorders [1] - SciSparc is engaged in clinical-stage pharmaceutical developments, particularly in cannabinoid pharmaceuticals, with ongoing drug development programs targeting conditions such as Tourette syndrome, Alzheimer's disease, and autism spectrum disorder [4] Group 2: Collaboration and Patent Development - NeuroThera Labs has published an international patent application for a combination therapy involving 5-methoxy-2-aminoindane (MEAI) and Palmitoylethanolamide (PEA) [2] - The combination therapy aims to address obesity and MASLD, which affects over 890 million adults and approximately 30% of the global adult population, respectively [2] Group 3: Market Potential - The global weight loss drugs market was valued at approximately $37 billion in 2025 and is projected to reach $226 billion by 2035, driven by increasing awareness of obesity as a chronic disease [3] - The MEAI-PEA combination is expected to provide a safer and more cost-effective alternative to GLP-1 agonists for treating obesity and MASLD [2][3]

Core Viewpoint - SciSparc Ltd. announced that its majority-owned subsidiary NeuroThera Labs Inc. will acquire approximately 54.01% of CliniQuantum Ltd. through a definitive share purchase agreement, enhancing its portfolio in the pharmaceutical and quantum technology sectors [1][3]. Company Overview - SciSparc Ltd. focuses on clinical-stage pharmaceutical developments, particularly in cannabinoid pharmaceuticals, with ongoing drug development programs targeting conditions such as Tourette syndrome, Alzheimer's disease, and autism spectrum disorder [7]. - NeuroThera Labs Inc. is dedicated to developing novel therapeutics for central nervous system disorders and other underserved health conditions [8]. Transaction Details - NeuroThera will acquire 56,375 CliniQ Shares, representing approximately 54.01% of CliniQ's issued and outstanding ordinary shares, from the Selling Shareholders [3]. - The consideration for the Purchased Shares includes 56,600,000 common shares of NeuroThera, valued at approximately $9,459,954.20 based on the average trading price over the preceding 20 days [4]. - Selling Shareholders may receive earn-out payments of up to $2,500,000, contingent upon achieving specific milestones, including payments for patent applications and a percentage of fundraising proceeds [5]. Closing Timeline - The closing of the transaction is expected within 30 days after submitting an application for an Israeli tax ruling, anticipated around March 31, 2026, subject to closing conditions [6].

SciSparc (SPRC)announced that it intends to effect a one-for-nine reverse share split of the Company’s issued and outstanding ordinary shares, no par value per share, effective at the market open on March 4, 2026. The Ordinary Shares will continue to trade on the Nasdaq Capital Market under the existing trading symbol “SPRC” and will begin trading on a split-adjusted basis at the market open on March 4, 2026. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ...

Core Viewpoint - SciSparc Ltd. announced a one-for-nine reverse share split effective March 4, 2026, which will reduce the number of outstanding shares from approximately 5,089,501 to about 565,500 [1][2]. Group 1: Reverse Share Split Details - The reverse share split will not change shareholders' percentage of ownership, except for minor adjustments due to fractional shares [2]. - Fractional shares will not be issued; instead, they will be rounded to the nearest whole share at the DTC participant level [2]. - The exercise price and the number of shares for outstanding options and warrants will be proportionately adjusted, with no fractional shares issued upon exercise [2]. Group 2: Shareholder Actions - Shareholders holding shares in book-entry form or through brokerage accounts do not need to take any action, as the exchange will be processed automatically by brokers or custodians [3]. Group 3: Company Overview - SciSparc, through its subsidiary NeuroThera Labs Inc., focuses on clinical-stage pharmaceutical developments, particularly in cannabinoid pharmaceuticals [4]. - The company is developing drugs such as SCI-110 for Tourette syndrome and SCI-210 for autism spectrum disorder and status epilepticus [4]. - SciSparc also has a controlling interest in a subsidiary that sells hemp seed oil-based products on Amazon [4].

Following the reverse share split, the Company will have approximately 565,000 outstanding shares, out of which approximately 561,533 will be publicly held Tel Aviv, Israel, March 02, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (“SciSparc” or the “Company”) (Nasdaq: SPRC), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today that it intends to effect a one-for-nine (1-for-9) reverse share split (the “Reverse Share Split”) of t ...

Core Viewpoint - SciSparc Ltd. announced that its majority-owned subsidiary NeuroThera Labs Inc. received a U.S. patent for a proprietary combination of antimicrobials and cannabinoids aimed at enhancing the efficacy of existing antibiotics against resistant bacterial strains [1][2]. Group 1: Patent and Technology - The newly granted U.S. patent complements existing patents in the U.S. and Europe, reinforcing global intellectual property protection for NeuroThera's antimicrobial-potentiating platform [2]. - The patented technology combines established antibiotics with cannabinoids like Δ⁹-Tetrahydrocannabinol (THC) and Cannabidiol (CBD), showing enhanced antimicrobial activity in pre-clinical studies against resistant Gram-positive pathogens such as MRSA [3][5]. - The platform aims to leverage the long-term safety data of these antibiotics to minimize risks while providing an effective and affordable therapeutic solution [3]. Group 2: Market Context and Need - Prolonged antibiotic use has led to the emergence of resistant bacterial strains, with MRSA causing approximately 130,000 deaths worldwide in 2021, a significant increase from 57,000 deaths in 2019 [4]. - The global antibiotics market is projected to reach approximately $58 billion in 2026, driven by the rising challenge of antimicrobial resistance [6]. - The "antimicrobial-sparing" effect of NeuroThera's combination may reduce the need for new antibiotics, addressing serious side effects associated with resistance development and organ toxicity [7]. Group 3: Industry Challenges - Pharmaceutical companies are increasingly reluctant to develop new antibiotics due to long development timelines, high costs, and rapid bacterial resistance, leading to a decline in innovation in this field [8].

Core Viewpoint - Neurothera Labs Inc. has received a U.S. patent for its proprietary combination of antimicrobials and cannabinoids aimed at enhancing the efficacy of existing antibiotics against resistant bacterial strains [1][2]. Company Summary - Neurothera Labs Inc. is a clinical-stage biotech company focused on developing innovative therapeutics, particularly in the area of antimicrobial resistance [10]. - The company is a majority-owned subsidiary of SciSparc Ltd. [1]. Technology and Innovation - The patented technology combines established antibiotics with cannabinoids like THC and CBD, demonstrating enhanced antimicrobial activity against resistant pathogens such as MRSA in preclinical studies [3][5]. - The platform aims to restore the effectiveness of antibiotics that are ineffective as monotherapy against resistant Gram-positive pathogens [3]. Market Context - The global antibiotics market is projected to reach approximately $58 billion in 2026, driven by the rising challenge of antimicrobial resistance [6]. - The emergence of resistant bacterial strains, particularly MRSA, has led to a significant increase in healthcare-acquired infections, with a reported 30% rise in the U.S. [6]. Antimicrobial Resistance Challenge - Prolonged antibiotic use has resulted in the emergence of resistant strains, with MRSA causing approximately 130,000 deaths worldwide in 2021, more than double the 57,000 deaths in 2019 [4]. - Overall, bacterial antimicrobial resistance caused 1.14 million deaths and was associated with 4.71 million deaths globally in 2021 [4]. Industry Dynamics - Pharmaceutical companies are increasingly reluctant to develop new antibiotics due to high costs and lengthy development timelines, leading to a gap in innovation as major firms exit the field [8][9]. - The need for innovative solutions that enhance the efficacy of existing antibiotics while improving safety is critical in the current landscape of antimicrobial resistance [6][7].

Core Insights - SciSparc Ltd. has acquired an IP portfolio from Xylo Technologies, including the MUSE™ system, targeting the global multi-billion dollar GERD device market [1][4] - The MUSE™ system is designed for transoral fundoplication, a minimally invasive procedure for treating gastroesophageal reflux disease (GERD) [2] - SciSparc plans to commercialize these technologies immediately and aims for rapid market penetration and revenue generation [2] Market Opportunity - The global GERD device market was valued at approximately $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030, with a CAGR of 3.24% from 2025 to 2030 [5] - SciSparc intends to replicate Xylo's successful commercialization model from Greater China in high-growth regions like North America, Europe, and Latin America [3] Acquisition Details - SciSparc acquired the complete portfolio of patents and related intellectual property rights associated with the MUSE™ system, issuing shares that represent 19.99% of its outstanding share capital to Xylo [4]

Core Viewpoint - SciSparc Ltd. announced a definitive agreement to acquire a portfolio of medical endoscopy patents, aiming to expand its presence in the medical device sector and accelerate commercialization plans [1][2][3]. Group 1: Acquisition Details - The acquisition includes patents, trademarks, and related rights associated with endoscopic systems and medical cameras, specifically the MUSE endoscopic system designed for minimally invasive procedures [2]. - The company plans to issue ordinary shares to the seller at closing, which will represent approximately 19.99% of the company's outstanding stock [4]. - SciSparc may opt to issue pre-funded warrants instead of some shares at its discretion [5]. Group 2: Commercial Strategy - SciSparc intends to commercialize the acquired technologies immediately after the deal closes, aiming to replicate existing successful distribution models [4]. - The company plans to leverage licensing and regional partnerships to expand its market reach in North America, Europe, and Latin America [4]. Group 3: Closing Conditions and Market Outlook - The acquisition is subject to customary conditions, including regulatory approvals, with an expected closing date by March 8, 2026 [6]. - A market research report indicates growth in the global GERD device market, driven by demand for innovative endoscopy systems, which may help SciSparc extend its reach into new medical segments alongside its pharmaceutical initiatives [6]. Group 4: Stock Performance - Following the announcement, SciSparc shares were trading lower by 12.07% to $1.27 [7].